Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01131039 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Dec 20, 2013 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 |
| clinicaltrials |
| NCT00005591 | Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Dec 13, 2013 | clinicaltrials |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Dec 10, 2013 | clinicaltrials |
| NCT01533727 | CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2013 | clinicaltrials |
| NCT00129558 | A Study to Evaluate PT-523 in Patients With Refractory Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00681148 | Botulinum Toxin Injection With Prostate Brachytherapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01504542 | Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Heat BiologicsINDUSTRY | 1 | Nov 21, 2013 | clinicaltrials |
| NCT00636298 | Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Nov 19, 2013 | clinicaltrials |
| NCT00072540 | S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 8, 2013 | clinicaltrials |
| NCT00095641 | S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 8, 2013 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
| NCT01674738 | TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV(SELECT-A) | withdrawn | Phase 2 | 0 | Aktion Bronchialkarzinom e.V.OTHER | 0 | Oct 11, 2013 | clinicaltrials |
| NCT01481233 | Oral Colchicine in Men With Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 0 | Sep 27, 2013 | clinicaltrials |
| NCT00085527 | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00385398 | QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 0 | Sep 2, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00685633 | Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Aug 20, 2013 | clinicaltrials |
| NCT01240941 | Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 20, 2013 | clinicaltrials |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Aug 14, 2013 | clinicaltrials |
| NCT01518140 | BiPAP-Vapotherm RCT | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2013 | clinicaltrials |
| NCT01105390 | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 2, 2013 | clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT01728181 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00026468 | Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis | withdrawn | Phase 2 / Phase 3 | 0 | University of UtahOTHER | 0 | Jul 24, 2013 | clinicaltrials |
| NCT00025519 | Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Jul 11, 2013 | clinicaltrials |
| NCT00003455 | Antineoplaston Therapy in Treating Women With Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00003536 | Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00080613 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | withdrawn | Phase 2 | — | Robert H. Lurie Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00084565 | Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | OncotherapeuticsINDUSTRY | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | The Cleveland ClinicOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00389766 | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma | withdrawn | Phase 2 | 0 | Children's Cancer and Leukaemia GroupOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT01614184 | Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT00006267 | Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jul 9, 2013 | clinicaltrials |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 27, 2013 | clinicaltrials |
| NCT01600807 | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01017822 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 0 | Jun 24, 2013 | clinicaltrials |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00369954 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | withdrawn | Phase 2 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Jun 10, 2013 | clinicaltrials |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01293942 | IXO+A in mCRC With Liver-only Metastases | withdrawn | Phase 2 | 0 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 5, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Dec 20, 2013source: clinicaltrials